GEN Exclusives

More »

Feature Articles

More »
Jun 15, 2011 (Vol. 31, No. 12)

Nudging Difficult-to-Express Proteins

Emerging Solutions Aim to Bring Challenging Targets Under Control

  • Chaperone Required

    Proteins often have hydrophobic patches that can initiate a hydrophobic collapse during their synthesis, making them difficult to express in heterologous systems. When such proteins are expressed in E. coli they tend to form inclusion bodies, and various tricks need to be employed. Fusion tags are often attached to proteins to help them solubilize, for example, and cleaved off during downstream processing. Yet even the best fusion partners don’t always guarantee that the now soluble proteins are properly folded.

    Pradman Qasba, Ph.D., chief of the structural glycobiology section at the National Cancer Institute, studies human glycosyltransferases. While the researchers have expressed and folded some of these family members in vitro, that method did not work for others. For example, Drosophila β-1,4-Galactosyltransferase-7 (β4Gal-T7) inclusion bodies could be folded in vitro but not human β4Gal-T7. The maltose binding protein (MBP)- β4Gal-T7 fusion was expressed successfully in E. coli, yet it showed poor solubility, and the β4Gal-T7 aggregated after proteolytic release from its MBP partner.

    Perhaps, Dr. Qasba reasoned, a different carbohydrate binding protein might succeed where MBP failed. “Sugar binding is similar to certain protein-protein interactions; sugars have hydrophobic surfaces, and hydrophobic surfaces bind with the hydrophobic cavity of the binding site in the lectins.” He hypothesized that the cavity in the sugar binding site of the lectins may be able to bind to and stabilize proteins with hydrophobic patches and prevent their collapse as they are folding.

    Galectins are known to specifically bind β-galactoside sugars. Dr. Qasba used human galectin-1 as a fusion protein to express soluble folded human β4Gal-T7 in E. coli. The fusion protein was captured on a lactose column, eluted, and cleaved. It was then selected by binding to a UDP column. “If it binds to that it is really folded—otherwise it would not be able to catch hold of that particular donor substrate,” he said. “This is the first time anyone has shown that galactins can act as a chaperone.”

    To date, Dr. Qasba’s lab has successfully expressed all three of the galectin-glycosyltransferases fusion proteins they have attempted. The vector has also been shared with several other labs in the U.S. and Europe. He isn’t betting that it will be the universal answer to the folding problem. But because galactin-1 is only one of a family of 17 related small proteins, it allows for many possibilities. “If one doesn’t work, perhaps another will.”

  • Make It Glow

    Click Image To Enlarge +
    Genentech researchers are working to determine the suitability of an expressed protein for structural studies before purification.

    Many proteins of therapeutic interest are membrane bound. By definition these mostly hydrophobic molecules are normally surrounded by a lipid bilayer. Obtaining sufficient quantities of purified, properly folded protein from solubilized cellular membranes can present a great challenge.

    When Genentech structural biology scientist Christopher Koth’s group is presented with a new protein target, the protein must be expressed to sufficient levels, purified, and then its high-resolution structure determined through crystallization or NMR.

    The process usually involves generating a large number of constructs. This is because they typically want to determine the minimal active fragment of the protein suitable for structure studies or test mutations that may stabilize the purified protein. Often, the native full-length proteins simply won’t express. And they have many targets to evaluate.

    “We run into this problem of having an early bottleneck, where we try to screen and identify those constructs that are most likely to yield us high-resolution crystal structures, or be amenable to structural studies by NMR.”

    What if they could determine the suitability of an expressed protein for structural studies before purification? Perhaps it could be made visible in the context of all the other proteins in a cell—like looking for a bright yellow four leaf clover in a field of green clover—and there was a measure of how amenable it might be to those structural studies?

    Fusing expressed proteins to a fluorescent protein, like GFP, is one possible solution. However, Genentech uses a standard HIS tag, and Koth didn’t want to change any of the cloning or expression pipeline. So, he and chemist Zachary Sweeney used a fluorophore that attaches to the HIS tag, as a result they were able to visualize the proteins as they came through a size exclusion column (SEC).

    Experience has shown that proteins that give a good SEC chromatography profile may crystallize. “On the other hand, proteins that give a lousy profile almost never crystallize,” he explained. “Multiple peaks, asymmetric peaks, or peaks in the wrong spot—if we see that, we drop the construct and don’t proceed to purification.”

    Koth uses a silica-based size-exclusion resin that can be run at very high flow rates. “We can do one run every approximately 20 minutes, so overnight we can screen a very large number of constructs,” he explained.

    For some challenging targets, like membrane proteins, maybe only 10–20 constructs from a 96-well plate will behave well by the SEC test. While that may not seem like such a magic bullet assay—especially since there are no guarantees that they will indeed crystallize—it represents “a significant time savings for us,” Koth noted. It means “we can screen more constructs, and that increases our chances of coming up with something that’s going to give a high-resolution structure.”

  • Tips for Obtaining Integral Membrane Proteins

    James C. Samuelson, Ph.D., senior scientist at New England BioLabs, is investigating protein fusion strategies and novel E. coli host strains for efficient expression of heterologous membrane proteins. He shares six tips for obtaining integral membrane proteins:

    • If using a bacterial host, the standard T7 system [BL21(DE3) strain plus T7 vector] will likely be too robust. Moderating expression with a tunable T7 expression system can facilitate proper membrane integration. Commercially available tunable T7 expression strains include BL21-AI, Single step KRX, Tuner(DE3), and Lemo21(DE3).
    • Test several inducer concentrations. Expression analysis may be aided by fusing the membrane protein to a reporter protein (e.g., GFP).
    • Use a low to medium copy vector with kanamycin or chloramphenicol selection. High-copy number plasmids (e.g., pUC origins) will almost certainly result in loss of plasmid by a fraction of the cells within the culture.
    • At the point of induction, analyze the cell population for maintenance of the expression construct (by plating cells with and without antibiotic).
    • Always determine how much of the protein is in the membrane fraction and extractable by detergent before scaling up.
    • Inducing at an early stage (OD600 = 0.4) and expression at low temperature (20°C) for a longer time (16 hours or more) generally results in a higher yield of membrane-integrated protein.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?